Robert Ora Felsch Net Worth

The estimated Net Worth of Robert Ora Felsch is at least $2.47 millió dollars as of 20 August 2024. Robert Felsch owns over 3,567 units of Ardelyx Inc stock worth over $545,698 and over the last 2 years Robert sold ARDX stock worth over $1,922,807.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Felsch ARDX stock SEC Form 4 insiders trading

Robert has made over 9 trades of the Ardelyx Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Robert sold 3,567 units of ARDX stock worth $20,903 on 20 August 2024.

The largest trade Robert's ever made was selling 207,988 units of Ardelyx Inc stock on 6 May 2024 worth over $1,832,374. On average, Robert trades about 20,613 units every 65 days since 2022. As of 20 August 2024 Robert still owns at least 91,560 units of Ardelyx Inc stock.

You can see the complete history of Robert Felsch stock trades at the bottom of the page.

What's Robert Felsch's mailing address?

Robert's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.

Insiders trading at Ardelyx Inc

Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.

What does Ardelyx Inc do?

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.

Complete history of Robert Felsch stock trades at Ardelyx Inc

Ardelyx Inc executives and stock owners

Ardelyx Inc executives and other stock owners filed with the SEC include:

• Michael Raab,
  President, Chief Executive Officer, Director
• Michael G. Raab,
  Pres, CEO & Director
• David Rosenbaum,
  Chief Development Officer
• Elizabeth Grammer,
  Chief Legal and Administrative Officer
• Susan Rodriguez,
  Chief Commercial Officer
• Justin A. Renz CPA, MST, M.S.T., MBA,
  CFO & Chief Accounting Officer
• Geoffrey Block,
  Independent Director
• David Mott,
  Independent Chairman of the Board
• Richard Rodgers,
  Independent Director
• Gordon Ringold,
  Independent Director
• William Bertrand,
  Independent Director
• Jan Lundberg,
  Independent Director
• Robert Bazemore,
  Independent Director
• Onaiza Cadoret-Manier,
  Independent Director
• Susan Rodriguez,
  Chief Commercial Officer
• Justin Renz,
  Chief Accounting and Principal Financial Officer
• Dr. Laura A. Williams M.D., M.P.H.,
  Chief Medical Officer
• Dan Pavicich,
  Sr. Director of Market Devel.
• David P. Rosenbaum,
  Chief Devel. Officer
• Elizabeth A. Grammer,
  Chief Legal & Admin. Officer and Sec.
• Karen Harrigan,
  Sr. Director Market Devel.
• Robert C. Blanks,
  Chief Regulatory Affairs & Quality Assurance Officer
• Sarah O'Brien,
  Chief People Officer
• Kimia Keshtbod,
  Mang. of Corp. Communications & Investor Relations
• Jeffrey W. Jacobs,
  Chief Scientific Officer
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Patrick J Kerins,
  10% owner
• 15 Gp, Llc Nea,
  10% owner
• Jeremy S Caldwell,
  EVP, Chief Scientific Officer
• Mark Kaufmann,
  Chief Financial Officer
• Harry R Weller,
  10% owner
• Ravi Viswanathan,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter J Barris,
  10% owner
• Reginald Seeto,
  Chief Operating Officer
• Scott D Sandell,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Enterprise Associates 12, L...,
  
• Annalisa Jenkins,
  Director
• Paul Korner,
  EVP, Chief Medical Officer
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Eric Duane Foster,
  Chief Commercial Officer
• Enterprise Associates 12, L...,
  10% owner
• Partners 12, Limited Partne...,
  
• Mohamad Makhzoumi,
  10% owner
• Muna Bhanji,
  Director
• Mike Kelliher,
  See Remarks
• Narani Arasaratnam,
  VP, Corporate Controller
• Ventures Vii Lpcmea Venture...,
  
• Peter G Schultz,
  Director
• Ryan D Drant,
  10% owner
• George Jue,
  VP, Operations & Facilities
• Partners 12, Limited Partne...,
  
• Jeffrey W Jacobs,
  Chief Scientific Officer
• Robert Ora Felsch,
  See Remarks
• Robert Blanks,
  See Remarks
• Laura A Williams,
  Chief Medical Officer